Vancouver, Canada – 28 October, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced that RheumNow, a leading rheumatology news platform, has featured Augurex’s latest ACR Convergence 2025 data on the Anti-14-3-3eta Multiplex Test in its on-site coverage from Chicago, IL.
Watch the full RheumNow segment (2 min):
In the segment, Dr. Akhil Sood notes that “the biomarker can distinguish who has axSpA and who does not, and this is a promising step toward a simple diagnostic tool.”
This recognition highlights the growing awareness of the role SPINEstat® (Anti-14-3-3eta Multiplex Immunoassay Test) plays in improving early detection and aiding in more accurate clinical decision-making in patients with axial spondyloarthritis (axSpA).
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat® in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com